

The Honorable Xavier Becerra  
Secretary  
U.S. Department of Health and Human Services  
200 Independence Avenue, S.W.  
Washington, D.C. 20201

Chiquita Brooks-LaSure  
Administrator  
Centers for Medicare & Medicaid Services  
200 Independence Avenue S.W., Ste 314G  
Washington, D.C. 20201

April 22th, 2024

**Re: Withdraw Medicaid Rebate Stacking Policy from MDRP to Protect Patients & Providers**

Dear Secretary Becerra and Administrator Brooks-LaSure,

The undersigned patient organizations are writing to express our concerns about the proposed rebate “stacking” policy changes in the Medicaid Drug Rebate Program. As proposed in the rule, “Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program,” the Best Price reporting mechanics for manufacturers would be significantly changed if finalized under the current language and would pose uncertainty in terms of access for patients. While we commend CMS for addressing costs for patients through the Medicaid program, we have concerns there may be unintended consequences for patients as a result of this proposed rule.

We are amplifying a recent letter sent to your office signed by six major provider groups. In [the letter](#), concerns were raised that the aggregated price created by the stacking policy (i.e., all drug discounts provided to separate stakeholders throughout the supply chain are combined) would result in an artificial baseline price that is not sustainable for manufacturers. We worry these proposed changes could disrupt operations significantly, ultimately impacting the patients who depend on life-saving medicines by forcing them to forgo treatment or receive care in a higher-cost setting.

The provider groups fear that drug manufacturers might reduce or eliminate discounts in the supply chain resulting in further ripple effects, which could put patients in an untenable situation. We are deeply concerned that such a drastic change in the Medicaid policy could end up severely impacting patients and the treatment plans they rely on.

Patients are already experiencing higher rates of step therapy and prior authorization, which are creating increased access challenges for many people. We encourage you to withdraw this policy and work closely with patients and providers to ensure that well-intentioned policies will truly benefit all stakeholders.

Thank you for your time and we look forward to working together on this important issue.

Sincerely,

AiArthritis  
Amputee Coalition  
APS Foundation of America  
Arthritis Foundation  
Autoimmune Association  
Biomarker Collaborative  
Black, Gifted & Whole Foundation  
Bone Health and Osteoporosis Foundation  
California Chronic Care Coalition  
Celiac Disease Foundation  
Coalition of Skin Diseases  
Color of Gastrointestinal Illnesses  
Derma Care Access Network  
Foundation for Sarcoidosis Research  
Global Healthy Living Foundation  
HealthHIV  
Healthy Men Inc.  
HealthyWomen  
Hidradenitis Suppurativa Coalition  
HS Connect  
ICAN, International Cancer Advocacy Network  
Lupus Foundation of America  
MET Crusaders  
Multiple Sclerosis Foundation  
National Consumers League  
The National Adrenal Diseases Foundation  
Partnership to Fight Chronic Disease  
Schizophrenia & Psychosis Action Alliance  
Sjögren's Foundation  
Vasculitis Foundation  
We Are ILL